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Abstract
Mucopolysaccharidosis (MPS) VII is an ultra-rare, progressively debilitating, life-
threatening lysosomal disease caused by deficiency of the enzyme, β-glucuroni-
dase. Vestronidase alfa is an approved enzyme replacement therapy for MPS VII.
UX003-CL301 was a phase 3, randomized, placebo-controlled, blind-start study
examining the efficacy and safety of vestronidase alfa 4 mg/kg intravenously
administered every 2 weeks to 12 patients with MPS VII. Due to the rarity of dis-
ease, broad eligibility criteria resulted in a highly heterogeneous population with
variable symptoms. For an integrated view of the diverse data, the changes from
baseline (or randomization for the placebo period) in clinical endpoints were
grouped into three functional domains (mobility, fatigue, and fine motor + self-
care) and analyzed post-hoc as subject-level heat maps. Mobility assessments
included the 6-minute walk test, 3-minute stair climb test, Bruininks-Oseretsky test
(BOT-2) gross motor function subtests, and patient-reported outcome assessments
(PROs) related to movement, pain, and ambulation. Fatigue assessments included
the Pediatric Quality of Life Multidimensional Fatigue Scale and other fatigue-
related PROs. Fine motor + self-care assessments included BOT-2 fine motor
function subtests and PROs for eating, dressing, hygiene, and caregiver assistance.
Most subjects showed improvement in at least one domain. Two subjects improved
in two or more domains and two subjects did not show clear improvement in any
domain. Both severely and mildly affected subjects improved with vestronidase
alfa in clinical assessments, PRO results, or both. Heat map analysis demonstrates
how subjects responded to treatment across multiple domains, providing a useful
visual tool for studying rare diseases with variable symptoms.
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1 | INTRODUCTION
Mucopolysaccharidosis (MPS) VII (also known as Sly syn-
drome) is an ultra-rare, autosomal recessive, debilitating,
and life-threatening lysosomal disease caused by a defi-
ciency of the β-glucuronidase (GUSB) enzyme that aids in
the degradation of glycosoaminoglycans (GAGs).1,2 As a
result, GAGs such as dermatan, chondroitin, and heparan
sulfate, accumulate in a wide variety of tissues and cause
organ dysfunction. MPS VII may present in utero or at birth
with hydrops fetalis. Though disease manifestations can vary
widely, key symptoms include hepatosplenomegaly, cardiac
and pulmonary compromise, severe joint and bone abnor-
malities, cognitive impairment, corneal clouding, hearing
loss, and short stature. Based on a European data set, the
estimated worldwide prevalence is 0.01 in 100 000 live
births.3 Most patients with MPS VII die before the second or
third decade of life due to progressive organ dysfunction,
with a median age of survival for patients postnatally diag-
nosed of 42 months.4
Enzyme replacement therapy (ERT) has demonstrated
efficacy for other MPS disorders.5-9 In November 2017, the
ERT vestronidase alfa (recombinant human GUSB; rhGUS;
UX003) was approved by the FDA to treat pediatric and adult
patients with MPS VII10; this approval was based on efficacy
and safety data from the vestronidase alfa clinical trial pro-
gram.11-13 UX003-CL301 was a phase 3, randomized, placebo-
controlled, blind-start study in 12 subjects. In this novel design,
all subjects received at least 24 weeks of treatment with
vestronidase alfa, but began active treatment at one of four pre-
defined time points with pre-treatment placebo data serving as
individual controls.12 The primary analysis of this study was
published Harmatz et al, demonstrating that vestronidase alfa
4 mg/kg administered intravenously every other week reduced
urinary GAG levels by 65% after 24 weeks of treatment and
resulted in numerical improvement in a clinical multi-domain-
responder index (mean + 0.5, P = .0527).
Given the extreme rarity of MPS VII, the phase 3 eligibility
criteria were broad and resulted in a highly heterogeneous study
population with variable clinical manifestations and physical
and/or cognitive limitations. Here, we employed a heat map
analysis in order to understand the individual impact of treat-
ment in this diverse population. This analysis was proposed to
address regulatory authority requests for a subject-by-subject
analysis for the small and heterogeneous UX003-CL301 study.
Clinical endpoints for each subject were grouped into three
functional domains—mobility, fatigue, and fine motor + self-
care—and analyzed as subject-level heat maps. These domains
were selected because they allowed for similar clinical efficacy
results to be assessed in aggregate for each subject according to
major areas of known disease impairment such as, walking/hip
pain, lack of energy, and limited dexterity or independence in
daily care. By including both physical assessments and patient-
reported outcome assessment scores, an integrated heat map
analysis allowed us to assess the totality of response in each
domain.
2 | METHODS
2.1 | Study participants
Eligible subjects were 5-35 years of age and had a confirmed
diagnosis of MPS VII based on leukocyte or fibroblast glu-
curonidase enzyme assay or genetic testing; there was no
prerequisite leukocyte or fibrolast glucuronidase enzyme
level, as this value was determined by independent labs
using different assays and reference ranges. Subjects must
have had elevated urinary GAG (≥3× the mean normal age
range) at screening and have apparent clinical signs of a
lysosomal disease as determined by the investigator. Total
urine GAG level was determined by ARUP Laboratories
(Salt Lake City, Utah) and the normal age range details are
provided in Supporting Information Table S1.
2.2 | Study design
UX003-CL301 (NCT02230566; 2014-005638-71) was a
phase 3, randomized, placebo-controlled, blind-start (or sin-
gle-crossover), 48-week study examining the efficacy and
safety of vestronidase alfa 4 mg/kg IV in subjects with MPS
VII. Subjects were randomized (1:1:1:1) to 1 of 4 groups;
each group crossed over from treatment with placebo to
treatment with vestronidase alfa at a different pre-defined
time point (after 0, 8, 16, or 24 weeks) to obscure the start of
active therapy. The study sponsor, investigators, and sub-
jects were blinded to group assignment. Additional details of
the study design from the UX003-CL301 are reported in
Harmatz et al.12
2.3 | Assessments
Assessments included in the heat map analysis of study
UX003-CL301 were categorized into three domains—mobility,
fatigue, and fine motor + self-care (Supporting Information -
Table S2). All assessments were conducted every 8 weeks.
Mobility assessments included: 2- and 6-minute walk test
(2MWT, 6MWT)14; 3-minute stair climb test (3MSC)15;
Bruininks-Oseretsky test of motor proficiency (BOT-2) run-
ning speed and agility and balance16; clinical problem evalua-
tion (CPE) walking and running; MPS health assessment
questionnaire (MPS HAQ) walking, stairs, and movement17;
and PROMIS health assessment questionnaire (PROMIS) pain
or childhood health assessment questionnaire (CHAQ) pain
depending on the age of the subject.
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Fatigue assessments included the CPE fatigue assessment
and all sections of the Pediatric Quality of Life (PedsQL) Multi-
dimensional Fatigue Scale.18 In PedsQL, sleep/rest fatigue refers
to the ability to sleep through the night, wake feeling rested, and
the need for naps; general fatigue refers to the impact of fatigue
on the ability to perform daily activities; cognitive fatigue refers
to the impact of fatigue on attention, memory, and processing
speed; and total fatigue is a composite of the Sleep/Rest Fatigue
Scale, General Fatigue Scale, and Cognitive Fatigue Scale. Fine
motor + self-care assessments included the BOT-2 fine motor
precision and manual dexterity assessments, CPE fine motor
and self-care assessment, as well as theMPSHAQ dressing, eat-
ing and drinking, hygiene, and caregiver assistance assessments.
Assessments included in the primary analysis of UX003-
CL301 are reported in Harmatz et al.12 Endpoints for UX003-
CL301 were selected based on qualitative research (patient
interviews; unpublished) and previous clinical trials evaluating
other forms of MPS.5-9 While cognitive impairment was noted
in medical history, neurological assessments were not performed
during this study, as changes in such assessments likely require
a longer treatment duration.
2.4 | Analysis
The heat map analysis was proposed to address regulatory
authority requests for a subject-by-subject analysis for the small
and heterogeneous UX003-CL301 study. In this post-hoc analy-
sis, the change from randomization for the placebo period and
the change from baseline (last assessment prior to switching to
treatment) for the treatment period was calculated for each study
assessment, grouped into the mobility, fatigue, or fine motor
+ self-care domain, and analyzed as a subject-level heat map.
Heat map color was determined according to the range of
changes observed for all subjects by assessment (Tables 1–3).
The maximum absolute change for each assessment was sub-
divided into seven ranges - one with no change or missing data,
three levels of improvement, and three levels of worsening. The
maximum level of improvement or worsening for each range
interval was defined as ±33%, ±67%, or ± 100% of the maxi-
mum absolute change. For example, the maximum absolute
change for the 6MWT observed in any subject by treatment
week 24 was 105 m; therefore subjects in the lightest blue color
improved within +33% of the maximum absolute change
(1-35 m), subjects in the intermediate blue color improved
between 34% and 67% (36-70 m), and subjects in the deepest
blue color improved between 68% and 100% (71-105 m). The
heat map analysis is one approach to evaluate treatment response
with many endpoints in a population with a wide variety of clini-
cal disease manifestations in a descriptive, graphical presenta-
tion, without using statistical models to evaluate treatment effect. T
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Due to the rarity of MPS VII and the small number of
subjects in this trial, individual patient data will not be
shared in order to safeguard patient privacy.
3 | RESULTS
3.1 | Baseline
A total of 14 subjects were screened and two subjects withdrew
consent before initiating treatment. Twelve subjects (4 males,
8 females) enrolled, completed the study participation at US
sites, and were included in the final analysis. Seven subjects
had a confirmed diagnosis of MPS VII with genetic screening
and the remaining five subjects had a confirmed diagnosis
based on a leukocyte or fibroblast glucuronidase enzyme assay.
Subjects ranged from 8 to 25 years old (nine subjects were
<18 years old) and were from the US, Mexico, Brazil, or Por-
tugal. There were a total of two missed doses in two separate
subjects, one dose of vestronidase alfa at week 42 and one dose
of placebo at week 6.
Baseline demographics and characteristics demonstrated
a heterogeneous study population. Baseline evaluations for
assessments included in the heat map analysis are shown in
Supporting Information Table S3. All subjects had abnor-
malities in their medical history including: musculoskeletal
and connective tissue disorders (91.7% of subjects); nervous
system disorders (83.3%); cardiac disorders (75.0%); con-
genital, familial, and genetic disorders (75.0%); general dis-
orders and administration site conditions (75.0%); infections
and infestations (75.0%); respiratory, thoracic and mediasti-
nal disorders (75.0%); hepatobiliary disorders (66.7%); skin
and subcutaneous tissue disorders (66.7%); investigations,
including increased blood alkaline phosphatase, body weight
below normal, cardiac murmur, increased hepatic enzyme,
and normal menstruation (58.3%); surgical and medical pro-
cedures (58.3%, full list of procedures is provided in
TABLE 2 Heat map scoring range for fatigue assessments
Color
Total fatigue:
Δ = 11
General fatigue:
Δ = 14
Sleep/rest fatigue:
Δ = 13
Cognitive fatigue:
Δ = 18
CPE-fatiguea:
Δ = 2
[−32, −22] [−42, −29] [−38, −26] [−52, −35] [−5, −4]
[−21, −11] [−28, −15] [−25, −13] [−34, −18] [−3, −2]
[−10, −1] [−14, −1] [−12, −1] [−17, −1] −1
0 0 0 0 0
[1, 10] [1, 14] [1, 12] [1, 17] 1
[11, 21] [15, 28] [13, 25] [18, 34] [2, 3]
[22, 32] [29, 42] [26, 38] [35, 52] [4, 5]
Note: White cells (not shown in table, but included in Figure 1) indicate that the assessment was not completed.
Abbreviation: CPE, clinical problem evaluation.
aThe negative changes (from randomization for placebo period and from baseline for UX003 period) are displayed since decreasing in these scores indicates improvement.
TABLE 3 Heat map scoring range for fine motor and dexterity assessments
Color
BOT2-
fine:
Δ = 3
BOT2-
dexterity:
Δ = 2
CPE-
fine motora:
Δ = 1
CPE-
self carea:
Δ = 1
MPS HAQ-
dressinga:
Δ = 2
MPS HAQ-
eating and
drinkinga:
Δ = 1
MPS HAQ-
hygienea:
Δ = 1
MPS HAQ-
caregiver assista:
Δ = 5
[−7, −5] [−6, −5] −2 −3 [−6, −5] −3 −3 [−14, −10]
[−4, −3] [−4, −3] −1 −2 [−4, −3] −2 −2 [−9, −5]
[−2, −1] [−2, −1] −1 [−2, −1] −1 −1 [−4, −1]
0 0 0 0 0 0 0 0
[1, 2] [1, 2] 1 [1, 2] 1 1 [1, 4]
[3, 4] [3, 4] 1 2 [3, 4] 2 2 [5, 9]
[5, 7] [5, 6] 2 3 [5, 6] 3 3 [10, 14]
Note: White cells (not shown in table, but included in Figure 1) indicate that the assessment was not completed.
Abbreviations: BOT2, Bruininks-Oseretsky test of motor proficiency; CPE, clinical problem evaluation; MPS HAQ, MPS health assessment questionnaire.
aThe negative changes (from randomization for placebo period and from baseline for UX003 period) are displayed since decreasing in these scores indicates
improvement.
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Supporting Information Table S4); and gastrointestinal dis-
orders (50.0%).
Pervasive physical and cognitive impairments prevented
the assessment of some measures at baseline: three of the
12 subjects could not walk; nine of the 12 were not able to
perform pulmonary function tests (PFT); five of the 12 could
not perform the BOT-2 gross motor tests; and five of the
12 could not perform the visual acuity test.
3.2 | Heat map domain efficacy
The level of treatment response across domains for each
individual subject is demonstrated in Figure 1. Ten of the
12 enrolled subjects showed improvement (predominance of
blue shading) after crossing over to receive vestronidase alfa
in at least one of the three heat map domains.
3.2.1 | Mobility
Subjects A4, C3, and D12 demonstrated clear improvements
in more than one assessment in the mobility domain. After
receiving 24 weeks of active treatment, subject A4 showed
an increase of 83 m in the 6MWT, a reduction in the total
number of rest stops during the 6MWT, an increase of
11 steps in the 3MSC test, and improvement in a timed task
for stepping sideways over a beam. Both C3 and D12
showed declines in distance walked in the 6MWT during the
placebo period, but increases in distance walked after begin-
ning treatment with vestronidase alfa. These two subjects
also saw improvements in other mobility domains such as
balance or climbing stairs.
Subjects A7, B8, and B9 also showed some improvement
in the mobility domain. For example, subject B9 increased
the number of stairs climbed in 3 minutes and was able to
step sideways over a beam, which was not possible prior to
treatment with vestronidase alfa. Nevertheless, this same
subject showed little change in the 6MWT. The remaining
six subjects showed little to no improvement in the mobility
domain. It should be noted that a majority of the six
remaining subjects had advanced disease with physical
and/or cognitive impairment at baseline, including two sub-
jects that required the use of a wheelchair; these cognitive
and physical impairments likely limited their ability to com-
prehend test instructions and reliably complete the mobility
tasks.
3.2.2 | Fatigue
Subjects A4, B8, B9, B2, and D6 showed substantial improve-
ments in multiple fatigue assessments. Though subjects B8,
B2, and B9 saw some improvement during treatment with pla-
cebo, their fatigue scores continued to improve after crossing
over to receive vestronidase alfa and were sustained through
the active treatment phase. After 24 weeks of treatment, large
increases (corresponding to improvement) in fatigue scores,
most notably in cognitive fatigue, brought subject B8 into the
range reported for that of healthy children.19,20
Four subjects, A11, A7, C1, and C5, showed variable
improvement in fatigue. Subject A7 reported no difficulty
with sleep-related fatigue at baseline, which did not change
with treatment, but showed substantial improvement in cog-
nitive fatigue. Subject C1 also showed noteworthy improve-
ment in cognitive fatigue despite slight decreases in other
fatigue assessments at week 48. The delayed improvement
in fatigue scores for subject C5 coincided with the resolution
of an acute viral illness. The remaining three subjects
showed little to no improvement in the fatigue domain; how-
ever, two of these subjects showed clear improvement in the
mobility domain.
3.2.3 | Fine motor + self-care
Subjects A11 and B8 showed clear improvement in multiple
assessments within the fine motor + self-care domain, with
both subjects showing substantial improvement in the
assessments that often required caregiver assistance. Subject
B8 was unable to complete the BOT-2 assessments due to
cognitive impairment, but all 12 of the 18 MPS HAQ items
that scored “extreme difficulty” improved after 24 weeks of
treatment with vestronidase alfa.
Four subjects, A4, C5, C3, and B9, showed some improve-
ment in fine motor + self-care assessments. Subject A4 dem-
onstrated small improvements in both fine motor and self-care
assessments, more notably after 24 weeks of treatment with
vestronidase alfa. Subject C3 also showed small improvements
in more than one assessment, but improvement was noted with
both placebo and active treatment. Subject C5 saw greater
improvement in fine motor and dexterity assessments, while
subject B9 displayed greater improvements in the self-care
assessments. The remaining six subjects exhibited little to no
change in the fine motor + self-care domain. Two of these six
subjects had baseline scores that indicated minimal impairment
in self-care assessments, therefore there was less potential for
improvement.
3.3 | Safety
A summary of safety findings from this study can be found
in Harmatz et al.12 Briefly, all subjects experienced at least
one treatment-emergent adverse event (TEAE) during both
the placebo and vestronidase alfa treatment periods. There
were no deaths or discontinuations from the study. C5 expe-
rienced a viral illness at treatment week 24, which may have
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Mobility Fatigue Fine-Motor & Self-Care 
Week  8 16 24 32 40 48 Week  8 16 24 32 40 48 Week  8 16 24 32 40 48 
A4 
Female 
14.7-yrs 
6MWT (m) Total Fatigue BOT2-Fine 
2MWT (m) General Fatigue BOT2-Dexterity 
MPS HAQ-Walking* Sleep/Rest Fatigue CPE-Fine Motor* 
3MSC (Steps) Cognitive Fatigue CPE-Self Care*
MPS HAQ-Stairs*  CPE-Fatigue MPS HAQ-Dressing* 
BOT2-Running MPS HAQ-Eating & Drinking* 
BOT2-Balance MPS HAQ-Hygiene* 
MPS HAQ-Movement* MPS HAQ-Caregiver Assist* 
PROMIS-Pain* 
A11 
Female 
13.4-yrs 
6MWT (m) Total Fatigue BOT2-Fine 
2MWT (m) General Fatigue BOT2-Dexterity 
CPE-Walking* Sleep/Rest Fatigue MPS HAQ-Dressing* 
MPS HAQ-Walking* Cognitive Fatigue MPS HAQ-Eating & Drinking* 
MPS HAQ-Stairs*  CPE-Fatigue MPS HAQ-Hygiene* 
MPS HAQ-Movement* MPS HAQ-Caregiver Assist* 
CHAQ-Pain* 
A7 
Female 
11.5-yrs 
6MWT (m) Total Fatigue BOT2-Fine 
2MWT (m) General Fatigue BOT2-Dexterity 
MPS HAQ-Walking* Sleep/Rest Fatigue MPS HAQ-Dressing* 
3MSC (Steps) Cognitive Fatigue MPS HAQ-Eating & Drinking* 
MPS HAQ-Stairs* MPS HAQ-Hygiene* 
BOT2-Running MPS HAQ-Caregiver Assist* 
CPE-Running* 
BOT2-Balance 
MPS HAQ-Movement* 
CHAQ-Pain* 
B8 
Female  
8.5-yrs 
6MWT (m) Total Fatigue BOT2-Fine 
2MWT (m) General Fatigue BOT2-Dexterity 
CPE-Walking* Sleep/Rest Fatigue MPS HAQ-Dressing* 
MPS HAQ-Walking* Cognitive Fatigue MPS HAQ-Eating & Drinking* 
3MSC (Steps)  CPE-Fatigue MPS HAQ-Hygiene* 
MPS HAQ-Stairs* MPS HAQ-Caregiver Assist* 
MPS HAQ-Movement* 
CHAQ-Pain* 
B2 
Female 
12.8-yrs 
MPS HAQ-Walking* Total Fatigue BOT2-Fine 
MPS HAQ-Stairs* General Fatigue BOT2-Dexterity 
MPS HAQ-Movement* Sleep/Rest Fatigue CPE-Fine Motor* 
CHAQ-Pain* Cognitive Fatigue MPS HAQ-Dressing* 
CPE-Fatigue MPS HAQ-Eating & Drinking* 
MPS HAQ-Hygiene* 
MPS HAQ-Caregiver Assist* 
B9 
Male  
16.5-yrs 
6MWT (m) Total Fatigue BOT2-Fine 
2MWT (m) General Fatigue BOT2-Dexterity 
CPE-Walking* Sleep/Rest Fatigue MPS HAQ-Dressing* 
MPS HAQ-Walking* Cognitive Fatigue MPS HAQ-Eating & Drinking* 
3MSC (Steps) MPS HAQ-Hygiene* 
MPS HAQ-Stairs* MPS HAQ-Caregiver Assist* 
BOT2-Running 
BOT2-Balance 
MPS HAQ-Movement* 
PROMIS-Pain*  Worsening Improving 
Cells right of the green line- vestronidase alfa; 
Cells left of the green line – placebo 
FIGURE 1 Individual heat map response. The color of each cell is based on the change from randomization during placebo treatment or from
baseline during vestronidase alfa treatment; yellow indicates worsening, gray indicates no change, blue indicates improvement, and white indicates
when an assessment is unavailable. Each cell represents an 8-week interval. *The negative changes (from randomization for placebo period and
from baseline for UX003 period) are displayed since decreases in these scores indicate improvement. Abbreviations: 2MWT, 2-minute walk test;
3MSC (steps), 3-minute stair climb test; 6MWT, 6-minute walk test; BOT2, Bruininks-Oseretsky test of motor proficiency; CHAQ, childhood
health assessment questionnaire; CPE, clinical problem evaluation; MPS HAQ, MPS health assessment questionnaire; PROMIS, PROMIS health
assessment questionnaire
58 HALLER ET AL.
contributed to her lack of clear improvement in one of the
heat map domains.
Two subjects experienced a serious adverse event during
the vestronidase alfa treatment period. B8 experienced a
treatment-related averse event of anaphylactoid reaction
secondary to an accidentally high bolus infusion rate during
the first hour of vestronidase alfa administration; the infu-
sion was stopped and restarted the same day after the
event was resolved with treatment of oxygen, epinephrine,
hydrocortisone and diphenhydramine. D10 experienced a
Mobility Fatigue Fine-Motor & Self Care 
Week  8 16 24 32 40 48 Week  8 16 24 32 40 48 Week  8 16 24 32 40 48 
C1 
Female  
17.4-yrs 
CPE-Walking* Total Fatigue MPS HAQ-Dressing* 
MPS HAQ-Walking* General Fatigue MPS HAQ-Eating & Drinking* 
3MSC (Steps) Sleep/Rest Fatigue MPS HAQ-Hygiene* 
MPS HAQ-Stairs* Cognitive Fatigue MPS HAQ-Caregiver Assist* 
CPE-Gross* 
MPS HAQ-Movement* 
PROMIS-Pain* 
C5 
Female 
22.6-yrs 
6MWT (m) Total Fatigue BOT2-Fine 
2MWT (m) General Fatigue BOT2-Dexterity 
CPE-Walking* Sleep/Rest Fatigue MPS HAQ-Dressing* 
MPS HAQ-Walking* Cognitive Fatigue MPS HAQ-Eating & Drinking* 
3MSC (Steps)  CPE-Fatigue MPS HAQ-Hygiene* 
MPS HAQ-Stairs* MPS HAQ-Caregiver Assist* 
BOT2-Running 
BOT2-Balance 
MPS HAQ-Movement* 
PROMIS-Pain* 
C3 
Female  
22.5-yrs 
6MWT (m) Total Fatigue BOT2-Fine 
2MWT (m) General Fatigue BOT2-Dexterity 
CPE-Walking* Sleep/Rest Fatigue CPE-Self Care* 
MPS HAQ-Walking* Cognitive Fatigue MPS HAQ-Dressing* 
3MSC (Steps) MPS HAQ-Eating & Drinking* 
CPE-Stairs* MPS HAQ-Hygiene* 
MPS HAQ-Stairs* MPS HAQ-Caregiver Assist* 
BOT2-Running 
BOT2-Balance 
MPS HAQ-Movement* 
PROMIS-Pain* 
D10 
Male 
10.1-yrs 
6MWT (m) Total Fatigue BOT2-Fine 
2MWT (m) General Fatigue BOT2-Dexterity 
MPS HAQ-Walking* Sleep/Rest Fatigue MPS HAQ-Dressing* 
3MSC (Steps) Cognitive Fatigue MPS HAQ-Eating & Drinking* 
MPS HAQ-Stairs*  CPE-Fatigue MPS HAQ-Hygiene* 
MPS HAQ-
Movement* 
MPS HAQ-Caregiver Assist* 
CHAQ-Pain* 
D6 
Male  
10.5-yrs 
CPE-Walking* Total Fatigue BOT2-Fine 
MPS HAQ-Walking* General Fatigue BOT2-Dexterity 
MPS HAQ-Stairs* Sleep/Rest Fatigue MPS HAQ-Dressing* 
MPS HAQ-
Movement* 
Cognitive Fatigue MPS HAQ-Eating & Drinking* 
CHAQ-Pain* MPS HAQ-Hygiene* 
MPS HAQ-Caregiver Assist* 
D12 
Male  
25.3-yrs 
6MWT (m) Total Fatigue BOT2-Fine 
2MWT (m) General Fatigue BOT2-Dexterity 
CPE-Walking* Sleep/Rest Fatigue MPS HAQ-Dressing* 
MPS HAQ-Walking* Cognitive Fatigue MPS HAQ-Eating & Drinking* 
3MSC (Steps) MPS HAQ-Hygiene* 
MPS HAQ-Stairs* MPS HAQ-Caregiver Assist* 
BOT2-Running 
CPE-Running* 
BOT2-Balance 
CPE-Gross* 
MPS HAQ-
Movement* 
PROMIS-Pain* 
 Worsening Improving 
Cells right of the green line- vestronidase alfa; 
Cells left of the green line – placebo 
FIGURE 1 Continued
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craniocerebral injury from falling off the bed; this event was
considered unrelated to treatment, resolved, and no action
was taken with vestronidase alfa treatment.
Overall, there were no significant differences in exposure-
adjusted incidence rates of TEAE, defined as the total number
of occurrences of the TEAE divided by the total amount of
time subjects participated in the analysis group phase.
4 | DISCUSSION
MPS VII disease manifestations were highly variable and
clinical response to vestronidase alfa showed individual dif-
ferences across subjects within this study. Overall, the inte-
grated heat map analysis demonstrated that 10 of 12 subjects
showed improvement in at least one clinical efficacy domain
relevant to their specific disease manifestations. For the
mobility domain, half of all subjects displayed improvement
in either some or many assessments. In the fatigue domain,
five subjects showed clear improvement across assessments
and an additional four subjects showed variable improve-
ment. Two subjects demonstrated consistent improvements
in the fine motor + self-care domain, while an additional
four subjects showed variable improvement. Lastly, some
subjects demonstrated clear improvement in more than one
heat map domain, and two subjects did not show clear
improvement in any domain.
In some cases where there was little to no improvement,
advanced disease at baseline, such as developmental delay or
physical impairment, prevented some subjects from following
test instructions or completing tasks. In contrast, some sub-
jects displayed little impairment at baseline in a particular
task, such as the self-care assessment of eating, and therefore
there was little room for improvement. The heat map analysis
provided a clear integrated appreciation of how subjects
improved in symptoms relevant to how they experience MPS
VII—a disease with a highly variable set of manifestations.
The wide range of clinical manifestations of disease
observed in patients in this study was consistent with previous
reports of patients with MPS VII.1 It will be important to fol-
low these patients to evaluate long-term treatment, and com-
pare clinical outcomes with natural history data from patients
with MPS VII. Data from the ongoing long-term extension
study (UX003-CL202; NCT02432144) and the Disease Mon-
itoring Program (UX003-CL401; NCT03604835) in patients
with MPS VII with and without vestronidase alfa treatment
will help to provide a long-term understanding of disease pro-
gression and response to treatment.
This analysis represents one approach to evaluating treat-
ment response in a study with many endpoints, and did not
use statistical significance to evaluate treatment effect. The
grouping of these assessments was based on three specific
domains. Of note, these assessments could be determined
prospectively and used in different, related domains; or new
assessments could be used to evaluate other domains. This
analysis may be limited by the narrow margin that defined no
change as an absolute change of zero, compared to the vary-
ing levels of improvement and worsening defined as within
±33%, ±67%, or ±100% of the maximum absolute change.
Because the range was determined by the maximum absolute
change, there is no clinical definition for the equivalent range
of each assessment. Nevertheless, this approach is meant to
be visually interpreted at a high level, across multiple related
endpoints, on a per-subject basis. The ranges can also be
adapted to integrate even more levels of improvement or
worsening. The seven levels, including no change, used in
this heat map analysis were sufficient to detect a varied
response to treatment across subjects. For the assessment of
long-term therapeutic use, the heat map analysis can be used
to assess change from baseline over the course of several
months. For a more complete long-term analysis, it is likely
most effective to use the heat map analysis in conjunction
with other tools, such as comparing natural history data to that
of patients treated with vestronidase alfa.
Importantly, the heat map analysis was not intended to deter-
mine the overall impact for all subjects in the study, but rather
provide an understanding of how treatment with vestronidase
alfa affected each individual's experience of MPS VII. Such an
approach is valuable in conjunction with additional analyses,
when assessing heterogeneous diseases that may present and
progress differently in each individual, like MPS VII. A sub-
group analysis was not considered appropriate for this study
because of the small number of subjects included (N = 12).
Any subgroup analysis in this small heterogeneous population
would be confounded by including some patients in an assess-
ment for which they have little to no impairment at baseline
with some patients that have great baseline impairment.
This integrated heat map analysis demonstrates how sub-
jects responded to treatment across multiple domains, pro-
viding a useful visual tool for studying complex genetic
diseases that present with multiple, variable symptoms.
While not all subjects improved in one specific domain, this
visualization approach enabled assessment of how treatment
improved clinical outcomes that were inter-related and rele-
vant to each individual's disease manifestations. This tool
could be applied in other rare disease clinical trials including
case studies to evaluate the totality of clinical baseline and
outcome data on an individual subject basis.
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